Dihexa vs FGL
A side-by-side research comparison of Dihexa and FGL across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dihexa | FGL |
|---|---|---|
| Full name | Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) | FGL (NCAM-Derived Peptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Allosteric potentiator of HGF/c-Met signaling driving synaptogenesis, dendritic spine formation, and neuronal survival in hippocampal circuits. | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. |
| Molecular weight | 507.6 Da | ~1,800 Da |
| Half-life | 6-12 hours | 4-8 hours |
| Bioavailability | Moderate (oral/SubQ) | Moderate (SubQ, partial BBB crossing) |
| Typical dose | 10-20 mg (oral) or 2-5 mg (SubQ) | 1-5 mg/kg (research) |
| Frequency | Daily | Daily or every other day |
| Route | Oral or Subcutaneous | Subcutaneous |
Dihexa reported benefits
- Dramatic synaptogenesis
- Memory improvement
- Cognitive restoration potential
- Dendritic spine growth
- HGF/c-Met activation
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
Related comparisons
Research and educational reference only. Not medical advice.